NP137 clinical trial
NP137 is a first-in-human Phase I trial with a dose-escalation part followed by extension cohorts (The trial was conducted according to Good Clinical Practice guidelines, the Declaration of Helsinki and relevant French and European laws and directives. All patients provided written informed consent.